Published in Lab Business Week, October 1st, 2006
These initiatives include:
1) In-license phase II and III drugs and develop and bring to market products with long-term intellectual property protection.
2) Expand existing partnerships and joint venture relationships with biotechnology companies.
3) Foster new strategic alliances that deliver a stronger product...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.